Bong Jun Kwak

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Ki Byung Song · 10 shared papers, 2014–2024 · strength 1.44
   • Paper Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2023.977↗
   • Paper Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. DOI 10.1097/mpa.0000000000002218↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
2. Dae Wook Hwang · 10 shared papers, 2014–2024 · strength 1.44
   • Paper Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2023.977↗
   • Paper Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. DOI 10.1097/mpa.0000000000002218↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
3. Song Cheol Kim · 10 shared papers, 2014–2024 · strength 1.44
   • Paper Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2023.977↗
   • Paper Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. DOI 10.1097/mpa.0000000000002218↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
4. Yejong Park · 8 shared papers, 2021–2024 · strength 1.27
   • Paper Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2023.977↗
   • Paper Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. DOI 10.1097/mpa.0000000000002218↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
5. Woohyung Lee · 8 shared papers, 2021–2024 · strength 1.22
   • Paper Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2023.977↗
   • Paper Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. DOI 10.1097/mpa.0000000000002218↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
6. Kyu‐pyo Kim · 5 shared papers, 2022–2024 · strength 0.78
   • Paper Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2023.977↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
   • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
7. Baek‐Yeol Ryoo · 5 shared papers, 2022–2024 · strength 0.78
   • Paper Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2023.977↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
   • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
8. Changhoon Yoo · 5 shared papers, 2022–2024 · strength 0.78
   • Paper Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2023.977↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
   • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
9. Sarang Hong · 4 shared papers, 2021–2023 · strength 0.59
   • Paper Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. DOI 10.1097/mpa.0000000000002218↗
   • Paper Predictive Performance of Current Nodal Staging Systems in Various Categories of Pancreatic Cancer. DOI 10.1245/s10434-021-10641-7↗
   • Paper Usefulness of Inflammation-Based Prognostic Scores in Patients with Surgically Treated Pancreatic Ductal Adenocarcinoma. DOI 10.3390/jcm10245784↗
10. Min Kyu Sung · 3 shared papers, 2021–2024 · strength 0.49
    • Paper Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2023.977↗
    • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
    • Paper Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Loca… DOI 10.3390/biomedicines9111706↗
11. Eunsung Jun · 3 shared papers, 2021–2024 · strength 0.45
    • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
    • Paper Predictive Performance of Current Nodal Staging Systems in Various Categories of Pancreatic Cancer. DOI 10.1245/s10434-021-10641-7↗
    • Paper Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Loca… DOI 10.3390/biomedicines9111706↗
12. Do Hyun Park · 3 shared papers, 2022–2024 · strength 0.42
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
    • Paper Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Follo… DOI 10.4143/crt.2022.409↗
    • Paper Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenoca… DOI 10.1177/17588359221097190↗
13. Jin‐hong Park · 3 shared papers, 2022–2024 · strength 0.42
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
    • Paper Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Follo… DOI 10.4143/crt.2022.409↗
    • Paper Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenoca… DOI 10.1177/17588359221097190↗
14. Tae Jun Song · 3 shared papers, 2022–2024 · strength 0.42
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
    • Paper Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Follo… DOI 10.4143/crt.2022.409↗
    • Paper Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenoca… DOI 10.1177/17588359221097190↗
15. Dong Wan Seo · 3 shared papers, 2022–2024 · strength 0.42
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
    • Paper Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Follo… DOI 10.4143/crt.2022.409↗
    • Paper Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenoca… DOI 10.1177/17588359221097190↗
16. Sang Soo Lee · 3 shared papers, 2022–2024 · strength 0.42
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
    • Paper Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Follo… DOI 10.4143/crt.2022.409↗
    • Paper Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenoca… DOI 10.1177/17588359221097190↗
17. Dongwook Oh · 3 shared papers, 2022–2024 · strength 0.42
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
    • Paper Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Follo… DOI 10.4143/crt.2022.409↗
    • Paper Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenoca… DOI 10.1177/17588359221097190↗
18. Inkeun Park · 2 shared papers, 2024 · strength 0.33
    • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
19. So Heun Lee · 2 shared papers, 2022–2023 · strength 0.26
    • Paper Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Follo… DOI 10.4143/crt.2022.409↗
    • Paper Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenoca… DOI 10.1177/17588359221097190↗
20. Yoo Na Lee · 1 shared paper, 2024 · strength 0.19
    • Paper Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2023.977↗
21. Dakyum Shin · 1 shared paper, 2023 · strength 0.18
    • Paper Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. DOI 10.1097/mpa.0000000000002218↗
22. Hyehyun Jeong · 1 shared paper, 2024 · strength 0.16
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
23. Seung‐Mo Hong · 1 shared paper, 2024 · strength 0.16
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
24. Hyunseok Yoon · 1 shared paper, 2024 · strength 0.16
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
25. Sora Kang · 1 shared paper, 2022 · strength 0.12
    • Paper Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenoca… DOI 10.1177/17588359221097190↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.